A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation Meeting Abstract
| Authors: | Goldberg, A. D.; Samaniego, F.; Ohanian, M.; Koller, P. B.; Chandhok, N. S.; Sadiq, A. A.; Mahadevan, D.; Cherry, M. A.; Altman, J. K.; Burke, J. M.; Koontz, M. Z.; Villasboas, J. C. C.; Tomlinson, B.; Finn, L. E.; Reid, E. G.; Melear, J.; Priego, V.; Cobb, P.; Cull, E. H.; Conkling, P.; Cosgrove, D.; Roeker, L. E.; Tam, E.; Haney, D. N.; Hu, J.; Sinha, R.; Khan, N.; Rice, W. G.; Bejar, R. |
| Abstract Title: | A phase 1a/b trial of luxeptinib (CG-806) in patients with relapsed/refractory B-cell malignancies or acute myeloid leukemia and evaluation of new G3 formulation |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 5953 |
| Language: | English |
| ACCESSION: | WOS:001159900803239 |
| DOI: | 10.1182/blood-2023-181151 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work